Paradigm Biopharmaceuticals (ASX:PAR) has announced that it has received firm commitments for a capital raising totalling $16 million through a placement of fully paid ordinary shares to sophisticated and institutional investors. …
Paradigm completes $16 million capital raise to support global Phase 3 clinical trial
December 9, 2024 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Australian medtech secures funds to advance real-time breast cancer surgery technology
February 13, 2026 - - Australian Biotech -
The Dispatched Podcast 'Week in Review' - 13 February
February 13, 2026 - - Podcast -
PBAC to reconsider broader vaccine funding after late addition to March agenda
February 13, 2026 - - Latest News -
Ten years of process 'improvements' is almost the point, says Anne Ruston
February 13, 2026 - - Latest News -
Senate scrutiny of PBS rules after Canberra family highlights lack of biologic access
February 12, 2026 - - Latest News -
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News